Fight antibiotic-resistant bacteria with Alzheimer's drug

Fight antibiotic-resistant bacteria with Alzheimer's drug

We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

Alzheimer's drug for antibiotic resistance

The World Health Organization (WHO) recently pointed out that antibiotic resistance is increasing extremely worldwide. This poses great threats to global health. But researchers from Australia may now have found a solution to the problem.

Dangerous increase in antibiotic resistance

The increase in resistance to antibiotics presents the healthcare system with an ever increasing challenge. If the problem is not brought under control soon, researchers face a horror scenario. According to an older study by the Berlin Charité, there could be around ten million deaths from multi-resistant germs by 2050. In recent years, more and more governments and experts have announced that they want to step up the fight against antibiotic resistance. Australian researchers have now gained new insights into how the problem could possibly be solved.

The drug was originally intended for the treatment of Alzheimer's

As the Australian-New Zealand University Association / Ranke-Heinemann Institute reports, dangerous, antibiotic-resistant bacteria could soon be treated with a drug that was originally developed for Alzheimer's disease.

This has resulted in a joint research project by Griffith University and the University of Queensland in Brisbane.

The results of the experts were published in the specialist magazine "mBio".

According to the information, the researchers particularly looked at the antibacterial properties of PBT2.

It is a metal-transporting drug that was originally intended for the treatment of Alzheimer's and Huntington's disease.

One of the biggest health threats worldwide

According to Professor Mark von Itzstein, director of the Institute for Glycomics at Griffith University, this is exciting news. Mainly because antibiotic resistance is currently one of the biggest health threats worldwide.

"Over the past 30 years, many bacteria have developed resistance to a wide range of antibiotic drugs," the scientist explained in a press release.

"This has resulted in the current antibiotic treatment becoming ineffective, resulting in an increasing number of deaths from infectious diseases in Australia," said von Itzstein.

“If no new solutions are discovered, it is estimated that by 2050 antimicrobial, resistant bacteria will be responsible for over 10 million deaths worldwide. Now we have found another weapon that will help us save millions of lives! ”

Effective agent for the treatment of infectious diseases

Professor Mark Walker of the School of Chemistry and Molecular Biosciences at the University of Queensland states that even if PBT2 does not make it to the market for these diseases, it has nevertheless proven to be of great utility.

“This particular drug has passed phases 1 and 2 of clinical trials for Alzheimer's and Huntington's disease. It has also been shown to be well tolerated by human patients, ”he said in a message.

“PBT2 was developed to prevent the interaction between metals and human cells. The hope was that it would reduce the deposition of heavy metals in the brain, ”said Walker.

"With this in mind and knowing that the prevention of metal deposits is toxic to bacteria, we took a closer look at what effect PBT2 has against a wide range of antibiotic-resistant bacteria."

The results suggest that this drug has the capacity to fight antibiotic-resistant bacteria.

"Using PBT2 as an anti-antibiotic resistance agent is a whole new strategy," said Professor Walker.

"We may be able to reverse antibiotic resistance to the extent that antibiotics are again an effective tool in the treatment of infectious diseases." (Ad)

Author and source information

Video: Antibiotic Stewardship in Nursing Homes: How You Can Prevent Antibiotic Resistance (November 2022).